Immunotherapy Drugs Market by Therapy Area [Cancer (Solid Tumor and Malignant), Autoimmune & Inflammatory Diseases, Infectious Diseases, and Others], Type of Drugs [Monoclonal Antibodies, Adult Vaccines (Preventive Vaccines and Therapeutic Vaccines), Checkpoint Inhibitors, Interferons Alpha & Beta, Interleukins, and Others] - Global Opportunity Analysis and Industry Forecast, 2021-2027

ID: VPR/HC/212 Publishing Year: January 2021 Pages: 62 Format:   


Immunotherapy Drugs Market size was valued at xx million in 2019 and is expected to reach xx million by 2027.

Immunotherapy is a type of cancer treatment that helps immune system to fight with cancer. The immune system helps your body fight infections and other disease. It is created with white blood cells and organs and issues of the lymph system. Immunotherapy drugs are mostly used in the treatment of cancer and act by stimulating the immune system of body and generate an immune response aiding the production of antibodies. Antibodies produced against antigen kill the cancerous or tumor cells.
Segment Insight:

Increase in substitutes in existing market, and immunotherapy is another possibility to chemotherapy for the first line treatment is the factors e factors that support the growth of Immunotherapy Drugs Market. However, high cost of Immunotherapy Treatment and higher affliction rate in the product development cycle impede the market growth. Constantly, rising adoption of Immunotherapy Drugs from individuals suffering from chronicle diseases such as solid tumors in major factors expected to drive growth of the global market. However, quick approval of drugs and reduction in recurrence of diseases propel market growth. Conversely, immunotherapy as an alternative option to chemotherapy and use of immunotherapy as the first line of drug for the treatment of cancer provide growth to the Immunotherapy Drugs Market.

The Global Immunotherapy Drugs Market is segmented based on therapy area, type of drugs. Based on therapy area, it is divided into cancer, autoimmune & inflammatory diseases, infectious diseases, and others. Cancer is further divided into solid tumor and malignant tumor. By type of drugs, it is classified into monoclonal antibodies, adult vaccines, checkpoint inhibitors, interferons alpha & beta, interleukins, and others.

By Therapy Area Insight:

Based on therapy area, it is divided into cancer, autoimmune & inflammatory diseases, infectious diseases, and others. Cancer is further divided into solid tumor and malignant tumor. These next generation cancer treatment options point to the opportunity of new improved techniques of anticancer therapy.

By Type of Drugs Insight:

Immunotherapy Drugs, it is classified into monoclonal antibodies, adult vaccines, checkpoint inhibitors, interferons alpha & beta, interleukins, and others. Immunotherapy is termed as a biological therapy in which the primary aim is to improve the human immunity system to fight against diseases such as cancer and infectious diseases. 

Major Key Players:

The report provides a comprehensive analysis of the key players operating in the Immunotherapy Drugs Market, such as F. Hoffmann-La Roche AG, GlaxoSmithKline plc., AbbVie, Inc., Amgen, Inc., Merck & Co., Inc., Alligator Bioscience, UbiVac, Bristol-Myers Squibb, Novartis International AG, and AstraZeneca plc. Most of the key players in Immunotherapy Drugs Market are focusing on business expansion to gain a higher revenue share through the adoption of strategies, such as mergers and acquisitions and new product development.

Immunotherapy Drugs Market Key Segments:

By Therapy Area

  • Cancer
  • Solid Tumor
  • Malignant
  • Autoimmune & Inflammatory Diseases
  • Infectious Diseases
  • Others

By Type of Drugs

  • Monoclonal Antibodies
  • Adult Vaccines
  • Preventive Vaccines
  • Therapeutic Vaccines
  • Checkpoint Inhibitors
  • Interferons Alpha & Beta
  • Interleukins
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • UK
    • Italy
    • Spain
    • The Netherlands
    • Norway
    • Russia
    • Sweden
    • Switzerland
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • New Zealand
    • Taiwan
    • Thailand
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • South Arabia
    • South Africa
    • Chile
    • Columbia
    • Egypt
    • Iran
    • Israel
    • Turkey
    • Venezuela


Frequently Asked Questions
F. Hoffmann-La Roche AG, GlaxoSmithKline plc., AbbVie, Inc., Amgen, Inc., Merck & Co., Inc., Alligator Bioscience, UbiVac, Bristol-Myers Squibb, Novartis International AG, and AstraZeneca plc.

TABLE OF CONTENTS:

CHAPTER 1 MARKET INTRODUCTION

1.1. REPORT OVERVIEW

1.2. SCOPE OF THE STUDY

1.3. PRIMARY MARKET SEGMENTS

1.4. RESEARCH METHODOLOGY

CHAPTER 2 EXECUTIVE SUMMARY

2.1. C-LEVEL EXECUTIVE’S OVERVIEW AND PERSPECTIVES

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE

3.2. PRINCIPAL FINDINGS

3.2.1. Key investment pockets

3.2.2. Leading winning strategies

  3.2.3 Key Player Positioning

3.3. PORTERS FIVE FORCES OF COMPETITIVE ANALYSIS

 3.4. MARKET DYNAMICS

3.4.1. Drivers

3.4.2. Restraints

3.4.3. Opportunities

3.4.4. Impact Analysis

3.5. IMPACT OF COVID-19 ON THIS MARKET

CHAPTER 4 IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA

4.1. SYNOPSIS

4.1.1. Market size and forecast

4.2. CANCER

4.2.1. Key market trends

4.2.2. Growth factors and opportunities

4.2.3. Market size and forecast

4.3. AUTOIMMUNE & INFLAMMATORY DISEASES

4.3.1. Key market trends

4.3.2. Growth factors and opportunities

4.3.3. Market size and forecast

4.4. INFECTIOUS DISEASES

4.4.1. Key market trends

4.4.2. Growth factors and opportunities

4.4.3. Market size and forecast

CHAPTER 5 IMMUNOTHERAPY DRUGS MARKET, BY TYPE OF DRUGS

5.1. SYNOPSIS

5.1.1. Market size and forecast

5.2. MONOCLONAL ANTIBODIES

5.2.1. Key market trends

5.2.2. Growth factors and opportunities

5.2.3. Market size and forecast

5.3. ADULT VACCINES

5.3.1. Key market trends

5.3.2. Growth factors and opportunities

5.3.3. Market size and forecast

5.4. CHECKPOINT INHIBITORS

5.4.1. Key market trends

5.4.2. Growth factors and opportunities

5.4.3. Market size and forecast

5.5. INTERFERONS ALPHA & BETA

5.5.1. Key market trends

5.5.2. Growth factors and opportunities

  5.5.3. Market size and forecast

5.6. INTERLEUKINS

5.6.1. Key market trends

5.6.2. Growth factors and opportunities

5.6.3. Market size and forecast

CHAPTER 6 IMMUNOTHERAPY DRUGS MARKET, BY REGION

6.1 SYNOPSIS

6.2 North America

6.2.1 Key market trends

6.2.2 Competitive scenario

6.2.3 Key growth factors and opportunities

6.2.4 Market size and forecast

6.3 Europe

6.3.1 Key market trends

6.3.2 Competitive scenario

6.3.3 Key growth factors and opportunities

6.3.4 Market size and forecast

6.4 Asia Pacific

6.4.1 Key market trends

6.4.2 Competitive scenario

6.4.3 Key growth factors and opportunities

6.4.4 Market size and forecast

6.5 LAMEA

6.5.1 Key market trends

6.5.2 Key growth factors and opportunities

6.5.3 Market size and forecast

CHAPTER 7 COMPANY PROFILES

  7.1. F. HOFFMANN-LA ROCHE AG

7.1.1. Company overview

7.1.2. Company snapshot

7.1.3. Product portfolio

7.1.4. Business performance

7.1.5. Key strategic moves and developments

7.2. GLAXOSMITHKLINE PLC.

7.2.1. Company overview

7.2.2. Company snapshot

7.2.3. Operating business segments

7.2.4. Product portfolio

7.2.5. Business performance

7.2.6. Key strategic moves and developments

7.3. ABBVIE, INC.

7.3.1. Company overview

7.3.2. Company snapshot

7.3.3. Operating business segments

7.3.4. Product portfolio

7.3.5. Business performance

7.3.6. Key strategic moves and developments

7.4. AMGEN, INC.

7.4.1. Company overview

7.4.2. Company snapshot

7.4.3. Operating business segments

7.4.4. Product portfolio

7.4.5. Business performance

7.4.6. Key strategic moves and developments

7.5. MERCK & CO., INC.

7.5.1. Company overview

7.5.2. Company snapshot

7.5.3. Operating business segments

7.5.4. Product portfolio

7.5.5. Business performance

7.5.6. Key strategic moves and developments

7.6. ALLIGATOR BIOSCIENCE

7.6.1. Company overview

7.6.2. Company Snapshot

7.6.3. Operating business segments

7.6.4. Product portfolio

7.6.5. Business performance

7.6.6. Key strategic moves and developments

7.7. UBIVAC

7.7.1. Company overview

7.7.2. Company snapshot

7.7.3. Operating business segments

7.7.4. Product portfolio

7.7.5. Business performance

7.7.6. Key strategic moves and developments

7.8. BRISTOL-MYERS SQUIBB

7.8.1. Company overview

7.8.2. Company snapshot

7.8.3. Operating business segments

7.8.4. Product portfolio

7.8.5. Business performance

7.8.6. Key strategic moves and developments

7.9. NOVARTIS INTERNATIONAL AG

7.9.1. Company overview

7.9.2. Company snapshot

7.9.3. Operating business segments

7.9.4. Product portfolio

7.9.5. Business performance

7.9.6. Key strategic moves and developments

7.10. ASTRAZENECA PLC.

7.10.1. Company overview

7.10.2. Company snapshot

7.10.3. Product portfolio

7.10.4. Key strategic moves and developments


PURCHASE OPTIONS




    ADD TO CART

CONTACT US
CALL US ON
( +91-935-919-4956 )

CONTACT EMAIL
[email protected]
PURCHASE OPTIONS




    ADD TO CART

CONTACT US
CALL US ON
( +91-935-919-4956 )

CONTACT EMAIL
[email protected]